Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924007055 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849721601821507584 |
|---|---|
| author | Tusneem Janoudi Mrunali Jagdale Meng Wu Sanjana Gorlla Peisheng Zhang Ying Shao Li Li Sheryl R. Bowley Eugenio Marco Kai-Hsin Chang |
| author_facet | Tusneem Janoudi Mrunali Jagdale Meng Wu Sanjana Gorlla Peisheng Zhang Ying Shao Li Li Sheryl R. Bowley Eugenio Marco Kai-Hsin Chang |
| author_sort | Tusneem Janoudi |
| collection | DOAJ |
| format | Article |
| id | doaj-art-1abca2bbe45e4c8a80955300dae87c1a |
| institution | DOAJ |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-1abca2bbe45e4c8a80955300dae87c1a2025-08-20T03:11:37ZengElsevierBlood Advances2473-95292025-02-019480881310.1182/bloodadvances.2024014040Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathiesTusneem Janoudi0Mrunali Jagdale1Meng Wu2Sanjana Gorlla3Peisheng Zhang4Ying Shao5Li Li6Sheryl R. Bowley7Eugenio Marco8Kai-Hsin Chang9Editas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MAEditas Medicine Inc, Cambridge, MA; Correspondence: Kai-Hsin Chang, Editas Medicine Inc, 11 Hurley St, Cambridge, MA 02141;http://www.sciencedirect.com/science/article/pii/S2473952924007055 |
| spellingShingle | Tusneem Janoudi Mrunali Jagdale Meng Wu Sanjana Gorlla Peisheng Zhang Ying Shao Li Li Sheryl R. Bowley Eugenio Marco Kai-Hsin Chang Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies Blood Advances |
| title | Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies |
| title_full | Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies |
| title_fullStr | Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies |
| title_full_unstemmed | Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies |
| title_short | Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies |
| title_sort | nonclinical evaluation of hbg1 2 and bcl11a as genome editing targets for the treatment of β hemoglobinopathies |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924007055 |
| work_keys_str_mv | AT tusneemjanoudi nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT mrunalijagdale nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT mengwu nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT sanjanagorlla nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT peishengzhang nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT yingshao nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT lili nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT sherylrbowley nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT eugeniomarco nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies AT kaihsinchang nonclinicalevaluationofhbg12andbcl11aasgenomeeditingtargetsforthetreatmentofbhemoglobinopathies |